Segment Information (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2024

Dec. 31, 2023

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment for the three months ended September 30, 2024 and 2023 is as follows:

	Three Months Ended September 30, 2024
	Cell Therapy			BioBanking		Degenerative Disease		Other				Total
Net revenues	$	-		$	1,292	$	8,004	$	-			$	9,296
Cost of revenues (excluding amortization of acquired intangible assets)		-			238		3,645		-				3,883
Direct expenses		3,496			353		4,187		8,529				16,565
Segment contribution	$	(3,496	)	$	701	$	172	$	(8,529	)		$	(11,152	)
Indirect expenses									375		(a)		375
Loss from operations												$	(11,527	)
(a) Components of other
Amortization									375
Total other								$	375

	Three Months Ended September 30, 2023
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	-		$	1,427	$	2,359		$	-			$	3,786
Cost of revenues (excluding amortization of acquired intangible assets)		-			398		3,204			-				3,602
Direct expenses		4,887			350		1,901			9,074				16,212
Segment contribution	$	(4,887	)	$	679	$	(2,746	)	$	(9,074	)		$	(16,028	)
Indirect expenses										83,228		(b)		83,228
Loss from operations													$	(99,256	)
(b) Components of other
Change in fair value of contingent stock consideration										(39	)
Goodwill impairment										82,714
Amortization										553
Total other									$	83,228

Financial information by segment for the nine months ended September 30, 2024 and 2023 is as follows:

	Nine Months Ended September 30, 2024
	Cell Therapy			BioBanking		Degenerative Disease		Other				Total
Net revenues	$	-		$	3,857	$	32,231	$	-			$	36,088
Cost of revenues (excluding amortization of acquired intangible assets)		-			952		6,694		-				7,646
Direct expenses		12,383			1,216		14,385		28,159				56,143
Segment contribution	$	(12,383	)	$	1,689	$	11,152	$	(28,159	)		$	(27,701	)
Indirect expenses									1,377		(a)		1,377
Loss from operations												$	(29,078	)
(a) Components of other
Amortization									1,377
Total other								$	1,377

	Nine Months Ended September 30, 2023
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	-		$	4,062	$	6,597		$	-			$	10,659
Cost of revenues (excluding amortization of acquired intangible assets)		-			1,355		5,052			-				6,407
Direct expenses		53,505			780		6,799			31,481				92,565
Segment contribution	$	(53,505	)	$	1,927	$	(5,254	)	$	(31,481	)		$	(88,313	)
Indirect expenses										117,289		(b)		117,289
Loss from operations													$	(205,602	)
(b) Components of other
Change in fair value of contingent consideration liability										(104,339	)
Change in fair value of contingent stock consideration										(159	)
Goodwill impairment										112,347
IPR&D impairment										107,800
Amortization										1,640
Total other									$	117,289

Financial information by segment is as follows:

	Year Ended December 31, 2023
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	—		$	5,441	$	17,330		$	—			$	22,771
Gross profit		—			3,791		2,964			—				6,755
Direct expenses		28,694			1,752		9,720			40,876				81,041
Segment contribution		(28,694	)		2,039		(6,756	)		(40,876	)			(74,286	)
Indirect expenses										118,001		(a)		118,001
Loss from operations													$	(192,287	)
(a) Components of other
Change in fair value of contingent consideration liability										(104,339	)
Goodwill impairment										112,347
IPR&D impairment										107,800
Amortization										2,193
Total other									$	118,001

	Year Ended December 31, 2022
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	—		$	5,512	$	12,463		$	—			$	17,975
Gross profit		—			1,976		(3,666	)		—				(1,690	)
Direct expenses		75,379			1,699		10,859			56,261				144,198
Segment contribution		(75,379	)		277		(14,525	)		(56,261	)			(145,888	)
Indirect expenses										(120,288	)	(b)		(120,288	)
Loss from operations													$	(25,600	)
(b) Components of other
Change in fair value of contingent consideration liability										(126,277	)
Change in fair value of contingent stock consideration										186
Goodwill impairment										3,610
Amortization										2,193
Total other									$	(120,288	)